Departamento de Enfermagem Materno-Infantil e Saúde Pública, Escola de Enfermagem de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, SP, Brazil.
Instituto de Ensino e Pesquisa, Hospital Sírio-Libanês, São Paulo, SP, Brazil.
J Bras Pneumol. 2020;46(2):e20190290. doi: 10.36416/1806-3756/e20190290. Epub 2020 May 11.
Over the years, various recommendations have been made in pursuit of controlling resistance to antituberculosis drugs, especially multidrug resistance, in Brazil. Given the importance of standardizing those recommendations, the aim of this study was to describe the main recommendations of the Brazilian guidelines, primarily those related to the treatment and follow-up of cases of tuberculosis. From August through October of 2018, a document search was conducted via the websites of the Brazilian National Ministry of Health, the Brazilian National Tuberculosis Control Program, the JBP, and the Official Gazette of the Federal Republic of Brazil. Data were collected systematically by using a protocol designed specifically for this study. Documents published between 2004 and 2018 were selected. It was possible to understand and trace the history of the measures for the control of multidrug-resistant tuberculosis in Brazil from 2004, when the first documents related to the disease were published, up to 2018, when the second edition of the Brazilian National Guidelines for the Control of Tuberculosis was published. The contents of the documents were analyzed and grouped by case definition, diagnostic criteria, treatment, use of directly observed treatment; mechanisms of social protection for patients; data tools; and organization of care. This analysis allowed us to understand the efforts towards standardizing some measures in Brazil, not only identifying advances in the alignment with international prerogatives (case definition, incorporation of diagnostic technology, and treatment regimens) but also underscoring the need for greater clarity regarding the mechanisms of social protection and the organization of the care provided via the Brazilian health care system.
多年来,巴西一直在提出各种建议,以控制抗结核药物的耐药性,特别是耐多药结核。鉴于规范这些建议的重要性,本研究旨在描述巴西指南的主要建议,主要是与结核病例的治疗和随访相关的建议。2018 年 8 月至 10 月,通过巴西国家卫生部、巴西国家结核控制规划、巴西胸科协会和巴西联邦共和国官方公报的网站进行了文件检索。使用专门为此研究设计的协议系统地收集数据。选择了 2004 年至 2018 年期间发表的文件。从 2004 年首次发表有关该疾病的文件开始,到 2018 年发布第二版巴西国家结核病控制指南,我们可以了解和追踪巴西耐多药结核病控制措施的历史。对文件的内容进行了分析,并按病例定义、诊断标准、治疗、直接观察治疗的使用、患者社会保护机制、数据工具和护理组织进行了分组。这种分析使我们能够了解巴西在标准化某些措施方面所做的努力,不仅确定了在与国际优先事项保持一致方面的进展(病例定义、纳入诊断技术和治疗方案),而且还强调了需要更加明确社会保护机制和通过巴西卫生保健系统提供的护理的组织。